Cobra Biomanufacturing announces the appointment of Andrew Arrage as vice president, business development for the eastern US region
The opening of an East Coast sales office supports Cobra's continued expansion of its North American contract manufacturing business.
In his new position, Andrew Arrage will be responsible for creating strategic business opportunities, and fostering client relationships for Cobra's contract manufacturing services.
He brings over ten years experience in research and business development within the life sciences industry, most recently as business development executive with Chiltern International, a global full-service CRO.
Prior to Chiltern, he worked at BioReliance as senior manager of business development responsible for strategic marketing and new business generation for BioReliance's process development and cGMP manufacturing services.
He has an MBA in new venture analysis from the University of Tennessee and an MS in microbiology from Virginia Polytechnic Institute.
David Thatcher, chief executive of Cobra, commented: "80% of Cobra's business already originates from the US, this territory constitutes over 70% of the global biopharmaceutical sales".
"The strengthening of our US footprint will enable Cobra to consolidate its position in the world's most important pharmaceutical market".
"I am delighted to welcome Andrew to Cobra Biomanufacturing".
"His broad, professional experience of sales, marketing and business development in the biotechnology sector will greatly assist Cobra in expansion of its business."
